Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Aspira Pathlab & Diagnostics Limited (ASDL) is a leading pathology specialist in India, offering a wide range of diagnostic services.
The company operates with an asset-light model but faces high operational costs which it is working to optimize.
Aspira has a strong presence in Maharashtra and aims to strengthen its regional footholds before scaling operations.
The company is adopting new technologies like chatbots and patient engagement platforms to enhance customer experience.
Healthcare Services
Healthcare Service Provider
121 Cr
Low Risk
50.4
58.9
0.3
16.7
135.88
49.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Aspira Pathlab & Diagnostics Ltd (ASPIRA) is currently trading at 117.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aspira Pathlab & Diagnostics Limited (ASDL) is a leading pathology specialist in India, offering a wide range of diagnostic services. The company operates with an asset-light model but faces high operational costs which it is working to optimize. Aspira has a strong presence in Maharashtra and aims to strengthen its regional footholds before scaling operations. The company is adopting new technologies like chatbots and patient engagement platforms to enhance customer experience.
Over the past 52 weeks, Aspira Pathlab & Diagnostics Ltd has traded between a low of ₹49.00 and a high of ₹135.88. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aspira Pathlab & Diagnostics Ltd has a market capitalization of approximately 121.05. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aspira Pathlab & Diagnostics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 50.44 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 121.05 Cr, Aspira Pathlab & Diagnostics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aspira Pathlab & Diagnostics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aspira Pathlab & Diagnostics Ltd is 50.44. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
2
Neutral
5
Bullish
7
Bearish
16
Neutral
5
Bullish
25
Bearish
14
Neutral
0
Bullish
18
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
84.30 | 157 Cr | 31.25 | 2.99 | 0.00 | 9.53 | 9.10 | 0.00 | ||
85.00 | 151 Cr | 7.81 | 1.30 | 0.00 | 16.61 | 20.64 | 12.53 | ||
117.60 | 121 Cr | 50.44 | 16.73 | 0.00 | 16.62 | 13.17 | 13.75 | ||
68.05 | 114 Cr | 33.82 | 2.00 | 0.00 | 5.93 | 8.44 | 0.00 | ||
57.10 | 91 Cr | 17.26 | 1.57 | 0.00 | 8.97 | 8.79 | 4.43 | ||
121.00 | 84 Cr | 42.68 | 3.29 | 0.00 | 5.87 | 8.80 | 2.74 | ||
62.50 | 79 Cr | 16.00 | 1.57 | 0.00 | 9.83 | 13.44 | 8.08 | ||
| Median: 7 Co. | — | 84.30 | 114 Cr | 31.25 | 2.00 | 0.00 | 9.53 | 9.10 | 4.43 |
Promoter Classification
Following completion of an open offer, Aspira Pathlab & Diagnostics has classified Mr. Nikunj Mange and Mr. Jay Arvind Bhanushali as Promoters, effective upon completion of the open offer (dated June 11, 2026).
Promoter Reclassification
Aspira Pathlab & Diagnostics notifies BSE that upon completion of an open offer (effective June 11, 2026), Mr. Nikunj Mange and Mr. Jay Arvind Bhanushali have been classified as Promoters of the company.
Promoter Categorization
Disclosure dated 10‑Jun‑2026 under Regulation 29(2) of SEBI (SAST) stating Shraddha Jagdish Bhanushali (and PACs) has been categorized in the Promoter category of the company; Annexure 2 enclosed.
SAST Disclosure
Raj Arvind Bhanushali and persons acting in concert disclosed under Reg.29(2) (SEBI SAST) acquisition of 6,39,674 equity shares (6.21%) of Aspira Pathlab & Diagnostics Ltd pursuant to an open offer.
Acquisition disclosure
Disclosure under Reg.29(2) SAST: Raj Arvind Bhanushali (with PACs) acquired 639,674 equity shares (6.21%) of Aspira Pathlab & Diagnostics Ltd (Scrip: 540788) pursuant to an open offer; acquirers are part of the promoter group.
Substantial Acquisition
Jay Arvind Bhanushali (with PACs) disclosed acquisition of 511,738 equity shares (4.97%) of Aspira Pathlab & Diagnostics Ltd pursuant to an open offer; additional PAC acquisitions were also reported under Reg 29(2).
